Dr. Reddy's Laboratories Ltd

RDY Healthcare Drug Manufacturers Specialty & Generic

Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025. In the quarter to June 2026, revenue fell 14.4%, EPS fell 70.0%, free cash flow fell 143.4% and total debt rose 34.0%, each against the same quarter a year earlier.

13.05 0.15 +1.16%
Market cap
$10.7B
P/E
32.9×
Fwd P/E
24.3×
Dividend yield
0.00%
F-score
4/9
Altman Z
5.26
Beneish M
−2.59
Dividend safety
74/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
8.21% 11.40% 16.28% 17.45%

+8 more TTM periods

Piotroski F-Score
5 4 4 3
ROA
5.55% 7.63% 10.88% 11.62%
ROIC
5.89% 8.55% 11.88% 13.05%
Return on Tangible Assets
12.38% 17.09% 22.80% 25.02%
Average Days of Receivables
112.81 110.01 106.53 101.85
Free Cash Flow per Share
0.18 0.26 0.35 0.26
Free Cash Flow
139.00 215.00 288.00 220.00
Capital Expenditures
(287.00) (392.00) (429.00) (453.00)
Other line items
Cash ROIC
2.43% 3.70% 4.91% 3.98%
Accounts Receivable Turnover
3.16 3.35 3.54 3.74
Accounts Payable Turnover
4.12 4.38 4.03 3.91
Inventory Turnover
1.98 2.05 2.06 2.01
Average Days of Payables
84.13 76.84 93.93 96.21
Days of Inventory on Hand
180.59 176.13 181.86 181.38
Tax Rate
(0.21) (0.23) (0.23) (0.23)
Research and Development Expense of Revenue
7.10% 7.15% 7.47% 7.70%
Selling, General and Administrative Expense of Revenue
33.24% 31.76% 29.80% 29.30%
Share Based Compensation of Revenue
0.09% 0.08% 0.10% 0.13%
Interest Coverage
8.52 13.48 19.90 22.03
Operating CF/Net income
1.26 1.33 1.11 0.99
Depreciation/Fixed assets
0.18 0.18 0.17 0.17
Capex/Depreciation
(1.30) (1.78) (1.94) (2.08)
Revenue per Share
4.39 4.30 4.73 4.74
Operating CF per Share
0.54 0.73 0.86 0.81
Capex per Share
(0.37) (0.47) (0.52) (0.54)
Capex to Sales
0.08 0.11 0.11 0.11

Fold the line items

Columns are period end dates